Andreas Ladurner
Founder, Managing Director & Chief Scientific Officer Eisbach Bio
Seminars
Wednesday 28th January 2026
Advancing ALC1 Inhibition With EIS-12656 to Deliver Next-Generation Clinical Impact in DDR Therapeutics
12:00 pm
- Update on on-going Phase I study with the first-in-class ALC1 inhibitor EIS-12656, including safety and tolerability.
- Connecting clinical Phase II plans with mechanistic and biomarker insights to shape advancement strategy
- Building a modular Phase II framework to expand tumor applicability, unlock synthetic-lethal and combinatorial therapy potential to enable ALC1 inhibition in solid tumor therapy
